Results 51 to 60 of about 21,331 (238)

Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism [PDF]

, 2015
© 2015 Wiley Periodicals, Inc. Acknowledgement Grant sponsor: State of Lower Saxony-Israel Research Cooperation; Grant number: ZN2035; Grant sponsor:German Research Council; Grant number: SFB/TRR43 and FOR1336; Grant sponsor: Parkinson UK; Grant number ...
Akarasereenont, Amedei, Angstwurm, Balachandra, Bermejo, Bettelli, Boucheron, Brenner, Brück, Byrd, Chatterjee, Chiang, Coles, Cossburn, Cuzzocrea, Cuzzocrea, Das Sarma, Doyle, Dugo, Fischer, Fitzner, George, Ghoreschi, Goldmann, Gorina, Gray, Haider, Hanamsagar, Hanisch, Hanisch, Hanisch, Hoffmann, Hong, Horwood, Jaleel, Jefferies, Kahlenberg, Kann, Kawai, Kelly, Khan, Krady, Langer-Gould, Lee, Lehmann, Lehmann-Horn, Lehnardt, Levitzki, Li, Lin, Liu, Liu, Lopez-Talavera, Mangla, Marzocco, Mattsson, Mauro, McDonald, McGeer, Mehta, Mijovic, Mohamed, Moore, Muelas-Serrano, Mukhopadhyay, Murray, Novogrodsky, Perry, Prinz, Raghavan, Ramdas, Regen, Rossum, Ruetten, Sagara, Scheffel, Schmidt, Schweingruber, Simmons, Soltoff, Spitzer, Stewart, Terada, Turpaev, Tönges, Wang, Wang, Weber, Weber, Wüst, Xiao, Zhang, Zorn   +92 more
core   +1 more source

Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function

eJHaem, 2021
All irreversible Bruton tyrosine kinase (Btk) inhibitors including ibrutinib and acalabrutinib induce platelet dysfunction and increased bleeding risk. New reversible Btk inhibitors were developed, like MK‐1026.
Bibian M.E. Tullemans, Mieke F.A. Karel, Valentine Léopold, Marieke S. ten Brink, Constance C.F.M.J. Baaten, Sanne L. Maas, Alex F. deVos, Johannes A. Eble, Marten R. Nijziel, Emiel P.C. van derVorst, Judith M.E.M. Cosemans, Johan W.M. Heemskerk, Theodora A.M. Claushuis, Marijke J.E. Kuijpers   +13 more
doaj   +1 more source

Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations

Molecules, 2022
Bruton’s tyrosine kinase (BTK) is a key protein from the TEC family and is involved in B-cell lymphoma occurrence and development. Targeting BTK is therefore an effective strategy for B-cell lymphoma treatment.
Xiangfan Yu, Simei Qiu, Dongshan Sun, Pei Guo, Quhuan Li   +4 more
doaj   +1 more source

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia

Journal of Hematology & Oncology, 2022
Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL).
Elizabeth M. Muhowski, Janani Ravikrishnan, Britten Gordon, Lianbo Yu, Shrilekha Misra, Brandi Walker, Sudharshan Eathiraj, Deepa Sampath, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach   +10 more
doaj   +1 more source

Combination of Ibrutinib and Venetoclax in the Therapy of Chronic Lymphocytic Leukemia: A Review of the Latest Data from Clinical Studies

Клиническая онкогематология, 2023
New Bruton’s tyrosine kinase (BTK) inhibitors caused drastic modifications in the therapy of chronic lymphocytic leukemia (CLL). Ibrutinib, the first in its class BTK inhibitor, showed high efficacy in many clinical studies.
A. A. Petrenko, Mariya Igorevna Kislova, E. A. Dmitrieva, E. A. Nikitin, V. V. Ptushkin   +4 more
doaj   +1 more source

Prolonged and tunable residence time using reversible covalent kinase inhibitors. [PDF]

, 2015
Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.
Angelina Bisconte, Dane E. Karr, Danny Tam, David Finkle, David G. Loughhead, David M. Goldstein, Erik Verner, J. Hill, J. Michael Bradshaw, Jack Taunton, Jens Oliver Funk, Jesse M. Mcfarl, Jin Shu, Ken A. Brameld, Mary E, Philip A. Nunn, Principia Biopharma, Sergei Romanov, Timothy D. Owens, Tony Ton, Vaishali Patel, Vernon T. Phan, Ville O. Paavilainen, Xiaoyan Li   +23 more
core  

Natural Products Inspired Scaffold Diversification Leads to Unnatural Molecular Warhead and Covalent Strategy to Modulating Protein Function through Electrophilic Bromine Transfer

Advanced Science, EarlyView.
We report a new thiolate‐reactive α,α‐gem‐dibromo lactam warhead that activates transcription factor Nrf2 and demonstrates anti‐inflammatory activities, which have implications in cancer, neurodegeneration, and cardiovascular diseases. RNA‐seq illuminated detailed transcriptional profiles, and chemical reactions with cysteine‐containing compounds ...
Beau R. Brummel, Sofia Kokkaliari, Qiwen Gao, Jinjing Chen, Larissa Costa de Almeida, Srinivasarao Tenneti, Derek A. Leas, Eli Levit, Lewis S. Alexander, Khalil A. Abboud, Pingrong Wei, Michael D. Cameron, James R. Rocca, Ranjala Ratnayake, Donna D. Zhang, Hendrik Luesch, Robert W. Huigens III   +16 more
wiley   +1 more source

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance

Blood and Lymphatic Cancer: Targets and Therapy, 2022
Frédérique St-Pierre,1 Shuo Ma1,2 1Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; 2Department of Medicine, Division of Hematology/Oncology, Feinberg ...
St-Pierre F, Ma S
doaj  

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies

Frontiers in Cell and Developmental Biology, 2021
Bruton’s tyrosine kinase (BTK) was discovered due to its importance in B cell development, and it has a critical role in signal transduction downstream of the B cell receptor (BCR).
Stefan F. H. Neys, Rudi W. Hendriks, Odilia B. J. Corneth   +2 more
doaj   +1 more source

Mechanically Robust Biodegradable Stents With Theragenerative Vascular Responses via Combined 3D Printing and Janus Nanoengineering

Advanced Science, EarlyView.
This work introduces a theragenerative 3D‐printed biodegradable stent with Janus nanoarchitecture for spatially controlled vascular healing. A luminal tantalum ion–implanted surface accelerates endothelialization and hemocompatibility, while an abluminal sirolimus/poly‐L‐lactic acid–tantalum layer provides sustained drug release and suppresses smooth ...
Jong Hwa Seo, Dong‐Sung Won, Hyun Lee, Seojoon Bang, Hyeong Seok Kang, Ju Yeong Gwon, Chan Ho Moon, Ji Won Kim, Yubeen Park, Minho Kang, Dong Yun Lee, Donghyun Lim, Kisuk Yang, Gi Doo Cha, Soo‐Hong Lee, Tae‐Sik Jang, Seokbeom Kim, Jun‐Kyu Park, Jung‐Hoon Park, Hyun‐Do Jung   +19 more
wiley   +1 more source